# A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06147570/  
OnCo record `nct06147570` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-10365 capsules in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06147570 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 62 participants planned, started 2023-09-25 and due to reach its primary completion in 2027-08-31. Interventions recorded: HS-10365 capsules.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06147570
- Phase: 2
- Setting: A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HS-10365 as First-Line Treatment for Patients With Locally Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT06147570: https://clinicaltrials.gov/study/NCT06147570

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06147570.json